Centene AI Stock Analysis
Want to see CNC full AI Analyst Report?
Centene (CNC) AI Stock Analysis
Centene
(NYSE:CNC)
The score is driven primarily by mixed financial performance—strong revenue and generally supportive cash generation, but notable earnings/ROE volatility. Technicals are a meaningful positive with the stock in a strong uptrend. The latest earnings call adds support via raised guidance and operational improvements, while valuation is a modest drag given a P/E that looks high relative to profitability consistency.
Centene Key Performance Indicators (KPIs)
Revenue by SegmentAnalyzes income from different business segments, revealing which areas are most profitable and where the company might expand or face challenges.
Medicaid and Medicare have become the growth drivers: Medicaid revenue climbs despite declining membership because mid‑year state rate actions and premium pass‑throughs are boosting dollars per member, while Medicare (PDP) shows a pronounced ramp as premium scale and favorable 2025 settlements lift revenue and margins. Commercial peaked in 2025 and has softened into 2026, consistent with Marketplace pressure and seasonality. Management warned some Q2 upside was nonrecurring, so focus on sustainable margin trends and membership/acuity risk when modeling forward earnings.
Centene (CNC) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $37.02B
- Dividend Yield
- ―
- Average Volume (3M)
- 4.88M
- Price to Earnings (P/E)
- 25.3
- Beta (1Y)
- 0.40
- Revenue Growth
- 9.71%
- EPS Growth
- ―
- Country
- US
- Employees
- 61,100
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Healthcare Plans
Centene Business Overview & Revenue Model
Company Description
Centene Corporation operates as a managed care company that provides programs and services to under-insured families, and commercial organizations in the United States. It operates through four segments: Medicaid, Medicare, Commercial, and Other. The...
How the Company Makes Money
Centene makes money primarily by operating managed care health plans and administering benefits for government-sponsored healthcare programs. Its largest revenue stream comes from premium revenue and capitation payments: state Medicaid agencies and t...
Centene Earnings Call Summary
The call was strongly positive overall. Centene delivered a better-than-expected third quarter, raised 2026 adjusted EPS guidance from more than $4.80 to more than $5.20, reported strong Medicare and Marketplace performance, reached an earlier-than-expected Medicare Advantage breakeven target, reduced debt, and described multiple operating and cost-management improvements. The primary challenges were Medicaid membership declines and work-requirement-related acuity risks, expected Medicare Advantage membership contraction, Marketplace membership attrition and program-integrity costs, the planned commercial-group exit, and a likely PDP margin reset in 2027. Highlights significantly outweighed the lowlights.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Centene raised 2026 adjusted diluted EPS guidance to >$5.20, with a full-year Medicaid HBR of approximately 93.5%, Medicaid membership down 8% to 9% year over year, a composite Medicaid rate of ~5%, Medicare Advantage reaching breakeven, PDP pretax margins in the mid- to high 3s, Marketplace pretax margin at the top of the previous 4.5% to 5.0% range, year-end Marketplace membership around 3.2 million, a full-year SG&A ratio midpoint of 7.2%, approximately $1.5 billion of investment and other income, and interest expense at a midpoint of $610 million; for 2027, the company expects to grow adjusted EPS relative to both the $4.70 jump off point and the revised $5.20 2026 guidance, with slight improvement in Medicaid HBR, Medicare Advantage better than breakeven, PDP membership growth, an improved SG&A rate, Medicaid membership attrition from OB 3, Medicare Advantage membership down year over year, Marketplace slight contraction, and an opening PDP margin expectation probably somewhere in 2% to 3% range.
Centene Financial Statement Overview
Summary
Strong revenue momentum and generally positive free cash flow support the core financial profile, and leverage appears manageable. However, profitability has been highly volatile (loss in 2025 followed by partial recovery), ROE remains negative in TTM, and cash flow has shown meaningful year-to-year swings—raising execution and medical cost/utilization risk.
Income Statement
52NeutralBalance Sheet
58NeutralCash Flow
61Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 203.90B | 194.78B | 163.07B | 154.00B | 144.55B | 125.98B |
| Gross Profit | 41.15B | 23.83B | 16.83B | 17.32B | 16.66B | 14.20B |
| EBITDA | 3.78B | -5.14B | 6.20B | 5.62B | 4.18B | 3.95B |
| Net Income | 1.46B | -6.67B | 3.31B | 2.70B | 1.20B | 1.35B |
Balance Sheet | ||||||
| Total Assets | 79.28B | 76.75B | 82.44B | 84.64B | 76.87B | 78.38B |
| Cash, Cash Equivalents and Short-Term Investments | 23.59B | 20.32B | 16.68B | 19.65B | 14.39B | 14.66B |
| Total Debt | 15.54B | 18.16B | 19.43B | 18.88B | 21.33B | 22.66B |
| Total Liabilities | 56.97B | 56.69B | 55.94B | 58.69B | 52.63B | 51.35B |
| Stockholders Equity | 22.21B | 19.95B | 26.41B | 25.84B | 24.06B | 26.80B |
Cash Flow | ||||||
| Free Cash Flow | 3.96B | 4.32B | -490.00M | 7.25B | 5.26B | 3.29B |
| Operating Cash Flow | 4.74B | 5.09B | 154.00M | 8.05B | 6.26B | 4.21B |
| Investing Cash Flow | 1.31B | 453.00M | -1.05B | -1.28B | -2.92B | -3.30B |
| Financing Cash Flow | -2.09B | -1.60B | -2.41B | -1.57B | -4.20B | 1.36B |
Centene Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CNC, the sentiment is Positive. The current price of 74.77 is above the 20-day moving average (MA) of 70.14, above the 50-day MA of 67.23, and above the 200-day MA of 56.79, indicating a bullish trend. The MACD of 1.32 indicates Negative momentum. The RSI at 61.98 is Neutral, neither overbought nor oversold. The STOCH value of 50.97 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CNC.
Centene Risk Analysis
Centene disclosed 34 risk factors in its most recent earnings report. Centene reported the most risks in the "Legal & Regulatory" category.
Latest Risks Added
3 New RisksCentene Peers Comparison
Overall Rating
OSCR77Outperform
ELV76Outperform
CI75Outperform
CNC67Neutral
HUM58Neutral
MOH53Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 77Outperform | $9.67B | 11.12 | 49.48% | ― | 54.77% | ― | |
| 76Outperform | $96.42B | 18.97 | 11.59% | 1.54% | 3.60% | -4.06% | |
| 75Outperform | $79.09B | 13.18 | 14.10% | 2.06% | 6.79% | -0.38% | |
| 67Neutral | $37.02B | 25.26 | 6.78% | ― | 9.71% | ― | |
| 58Neutral | $55.40B | 44.41 | 6.70% | 0.77% | 22.02% | -3.07% | |
| 53Neutral | $12.17B | -377.95 | -1.17% | ― | -0.95% | -105.84% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| CNC | Centene | 74.77 | 38.82 | 107.98% | |
| CI | Cigna | 300.16 | 34.20 | 12.86% | |
| HUM | Humana | 461.25 | 235.30 | 104.14% | |
| MOH | Molina Healthcare Inc | 233.09 | 94.97 | 68.76% | |
| ELV | Elevance Health, Inc. | 446.28 | 136.08 | 43.87% | |
| OSCR | Oscar Health, Inc. | 31.33 | 17.25 | 122.51% |
Centene Corporate Events
Centene Redeems Remaining 2027 Notes to Simplify Debt
PositiveOn October 8, 2026, Centene Corporation announced it had notified holders of its intention to redeem on October 23, 2026 all of the remaining $568.664 million principal amount of its outstanding 4.25% notes due December 15, 2027. The redemption will...
Centene Reaffirms 2026 Earnings Guidance at Healthcare Summit
PositiveCentene Corporation said it will participate in the Deutsche Bank 2026 Healthcare Summit on September 16, 2026, where management plans to discuss business performance and financial results. The company will reaffirm its full-year 2026 guidance for GA...
Centene Announces Planned Chief Financial Officer Transition
NeutralOn August 17, 2026, Centene announced a planned chief financial officer transition, with current CFO Drew Asher set to step down from the role on December 31, 2026 and retire from the company at the end of 2027, while remaining as a strategic advisor...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 05, 2026
